"Shares of Evofem Biosciences Inc jumped as much as  percent on Monday after its birth control gel showed effectiveness in a latestage study bringing the first hormonefree contraceptive close to approval.  Male condoms and oral pills dominate the . billion contraceptive market in the United States. However oral pills cause side effects such as bleeding between periods mood swings and nausea in women.  These results pave the way for Amphoras disruption of the contraception market as a novel highly effective nonhormonal and womancontrolled method that finally answers womens longawaited desire to avoid hormones Roth Capital Partners analyst Yasmeen Rahimi said.  Evofems Amphora gel works by regulating vaginal pH within the normal range of . to . creating a hostile environment for sperm and certain viral and bacterial pathogens that can cause sexually transmitted diseases.  An estimated . million women in the United States do not use any method of contraception according to the company on fear of side effects leaving them highly susceptible to unwanted pregnancies and sexually transmitted diseases.  Amphora was found to have an  percent efficacy rate in avoiding pregnancies and no serious sideeffects were observed in the study which evaluated about  healthy women belonging to the age group  years Evofem said.  Condoms the most common nonhormonal method of contraception have an efficacy rate of  percent. The rate stands at about  percent for oral pills and intrauterine devices according to brokerage Roth Capital Partners.  Our research and current understanding of women suggests the time is now for there to be a new nonhormonal category in contraception Chief Executive Saundra Pelletier said on a conference call with analysts.  The companys shares were up . percent at . in midmorning trade after touching a high of ..  Oppenheimer analyst Leland Gershell said he expects Amphora the companys lead product to bring in sales of up to  million by .  The company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved plans to launch the product in January .  Evofem is also testing Amphora as a preventive treatment for chlamydia and gonorrhea  two of the worlds most common sexually transmitted infections."